The role of surgical management for prolactin-secreting tumors in the era of dopaminergic agonists: An international multicenter report
Matthew C Findlay,Mohammadmahdi Sabahi,Mohammed Azab,Richard Drexler,Roman Rotermund,Franz L Ricklefs,Jörg Flitsch,Timothy R Smith,John L Kilgallon,Jürgen Honegger,Isabella Nasi-Kordhishti,Paul A Gardner,Zachary C Gersey,Hussein M Abdallah,John A Jane,Ulrich J Knappe,Nesrin Uksul,Henry W S Schroder,Márton Eördögh,Marco Losa,Pietro Mortini,Rüdiger Gerlach,Apio C M Antunes,William T Couldwell,Karol P Budohoski,Robert C Rennert,Michael Karsy
DOI: https://doi.org/10.1016/j.clineuro.2023.108079
Abstract:Objective: First-line prolactin-secreting tumor (PST) management typically involves treatment with dopamine agonists and the role of surgery remains to be further explored. We examined the international experience of 12 neurosurgical centers to assess the patient characteristics, safety profile, and effectiveness of surgery for PST management. Methods: Patients surgically treated for PST from January 2017 through December 2020 were evaluated for surgical characteristics, outcomes, and safety. Results: Among 272 patients identified (65.1% female), the mean age was 38.0 ± 14.3 years. Overall, 54.4% of PST were macroadenomas. Minor complications were seen in 39.3% of patients and major complications were in 4.4%. The most common major complications were epistaxis and worsened vision. Most minor complications involved electrolyte/sodium dysregulation. At 3-6 months, local control on imaging was achieved in 94.8% of cases and residual/recurrent tumor was seen in 19.3%. Reoperations were required for 2.9% of cases. On multivariate analysis, previous surgery was significantly predictive of intraoperative complications (6.14 OR, p < 0.01) and major complications (14.12 OR, p < 0.01). Previous pharmacotherapy (0.27 OR, p = 0.02) and cavernous sinus invasion (0.19 OR, p = 0.03) were significantly protective against early endocrinological cure. Knosp classification was highly predictive of residual tumor or PST recurrence on 6-month follow-up imaging (4.60 OR, p < 0.01). There was noted institutional variation in clinical factors and outcomes. Conclusion: Our results evaluate a modern, multicenter, global series of PST. These data can serve as a benchmark to compare with DA therapy and other surgical series. Further study and longer term outcomes could provide insight into how patients benefit from surgical treatment.